News Release

Altered microbiome linked to liver disease in adolescents with cystic fibrosis

Peer-Reviewed Publication

University of Colorado Anschutz Medical Campus

AURORA, Colo. (Feb. 18, 2015) - A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis.

In a research article published in the journal PLOS One, Michael Narkewicz, MD, professor of pediatrics, and his co-authors studied adolescents with cystic fibrosis and cirrhosis and compared them to adolescents with cystic fibrosis and no liver disease.

They found that those with liver disease had a different microbiome (gut bacteria), slower small bowel motility and more signs of small bowel inflammation compared to those without liver disease. This suggests that there is an interaction between the gut bacteria in cystic fibrosis and the liver that may lead to liver disease. The finding is important because it points to potential targets for therapy by suggesting specific reasons that some adolescents with cystic fibrosis develop advanced liver disease.

Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States have cystic fibrosis. Cirrhosis occurs in 5 percent to 7 percent of cystic fibrosis patients. Cirrhosis is a slowly progressing disease in which healthy liver tissue is replaced with scar tissue, eventually preventing the liver from functioning properly.

"While some intestinal symptoms are common in all cystic fibrosis patients," Narkewicz said, "we found there are some who have disturbances in intestinal function combined with changes in the gut microbiome that may contribute to liver disease. We hope this finding will point toward a better understanding of why only 5 to 7 percent of cystic fibrosis patients develop severe liver disease and will suggest potential therapies to help those patients."

###

Narkewicz joined the Department of Pediatrics at the CU School of Medicine and Children's Hospital Colorado in 1989. He was appointed professor of pediatrics in 2003. He has served as medical director of the pediatric liver center and liver transplantation program at Children's Colorado since 1998, as director of the fellowship program in pediatric gastroenterology since 2005 and as the director of clinical services in pediatric gastroenterology from 2006 to 2012.

This research was supported by a grant from the National Institutes of Health/National Center for Advancing Translational Sciences.

About the University of Colorado School of Medicine

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators and scientists at University of Colorado Health, Children's Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical school's care, education, research and community engagement, visit its web site.

Contact: Mark Couch, 303-724-5377, mark.couch@ucdenver.edu


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.